This HTML5 document contains 94 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/national-drug-code-directory/
n20http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/chebi/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n11http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00315/identifier/drugbank/
n25http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00315
rdf:type
n3:Drug
n3:description
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]
n3:dosage
n8:271B510A-363D-11E5-9242-09173F13E4C5 n8:271B510B-363D-11E5-9242-09173F13E4C5 n8:271B510C-363D-11E5-9242-09173F13E4C5 n8:271B510D-363D-11E5-9242-09173F13E4C5 n8:271B5106-363D-11E5-9242-09173F13E4C5 n8:271B5107-363D-11E5-9242-09173F13E4C5 n8:271B5108-363D-11E5-9242-09173F13E4C5 n8:271B5109-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9859690 # Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9399012
n3:group
investigational approved
n3:halfLife
The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.
n3:indication
For the acute treatment of adult migraine with or without auras.
n3:manufacturer
n9:271B50FB-363D-11E5-9242-09173F13E4C5 n9:271B50FA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00315 n26:DB00315
dcterms:title
Zolmitriptan
adms:identifier
n17:PA451975 n18:D00415 n21:0310-0208-60 n22:C07218 n23:10124 n24:DB00315 n27:Zolmitriptan
n3:mechanismOfAction
Zolmitriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
n3:packager
n9:271B50F5-363D-11E5-9242-09173F13E4C5 n9:271B50F6-363D-11E5-9242-09173F13E4C5 n9:271B50F4-363D-11E5-9242-09173F13E4C5 n9:271B50F9-363D-11E5-9242-09173F13E4C5 n9:271B50F7-363D-11E5-9242-09173F13E4C5 n9:271B50F8-363D-11E5-9242-09173F13E4C5
n3:patent
n7:5466699 n7:2064815 n7:2572508 n7:6750237
n3:synonym
Zomig (S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one Zolmitriptan Zolmitriptanum 311C90 4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
n3:volumeOfDistribution
* 8.4±3.3 L/kg
n19:hasAHFSCode
n20:28-32-28
n3:proteinBinding
25%
n3:synthesisReference
Islam Aminul, Bhar Chandan, Katam Sahadev, "Process for preparing optically pure zolmitriptan." U.S. Patent US20050245585, issued November 03, 2005.
n5:hasConcept
n6:M0237257
foaf:page
n11:zolmit.htm n12:zolmitriptan.html
n3:IUPAC-Name
n4:271B5112-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5118-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5117-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5114-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5115-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5116-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5110-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5128-363D-11E5-9242-09173F13E4C5 n4:271B510E-363D-11E5-9242-09173F13E4C5 n4:271B5111-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B510F-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n25:N02CC03
n3:H-Bond-Acceptor-Count
n4:271B511E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B511F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5119-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B511A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B511C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B511B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B511D-363D-11E5-9242-09173F13E4C5
n3:absorption
Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
139264-17-8
n3:category
n3:clearance
* 25.9 mL/min/kg
n3:containedIn
n13:271B5101-363D-11E5-9242-09173F13E4C5 n13:271B5102-363D-11E5-9242-09173F13E4C5 n13:271B50FF-363D-11E5-9242-09173F13E4C5 n13:271B5100-363D-11E5-9242-09173F13E4C5 n13:271B5105-363D-11E5-9242-09173F13E4C5 n13:271B5103-363D-11E5-9242-09173F13E4C5 n13:271B5104-363D-11E5-9242-09173F13E4C5 n13:271B50FD-363D-11E5-9242-09173F13E4C5 n13:271B50FE-363D-11E5-9242-09173F13E4C5 n13:271B50FC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5124-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5126-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5127-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5123-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5122-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5125-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5113-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5120-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5121-363D-11E5-9242-09173F13E4C5